Keywords: Roche, reMYND, Parkinson's, Alzheimers, License

Roche in 500 million-euro deal with reMYND to develop Parkinson’s and Alzheimer’s disease drugs

Article | 08 September 2010

Print This

Swiss drug major Roche (SIX: RO, ROG) has entered into an agreement with privately-held reMYND to develop novel therapeutics that ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in